# POLYMED (POLYMED) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/polymed

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,727.8
- Change: +0.88%
- As of: 2026-09-18
- 1D return: +0.78%
- 5D return: -1.24%
- 1M return: -2.46%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, POLYMED is trading at ₹1726.0. The stock exhibits a mixed technical stance across timeframes. Daily indicators suggest consolidation, with the price below key short-term moving averages like the 20-day EMA (₹1729.47) and 20-day SMA (₹1730.27), while remaining above the 50-day SMA (₹1723.94) and 200-day SMA (₹1585.68). The daily Supertrend is bullish at ₹1680.77. Weekly and monthly timeframes show a bullish Supertrend, indicating a potentially stronger underlying trend, though the monthly price is below its 20-day EMA (₹1797.33) and 20-day SMA (₹1836.28). The stock is currently positioned near the middle of its recent trading range, with the closest support identified at the pivot level of ₹1721.93, approximately 0.24% below the current price. Nearest resistance is observed at ₹1743.77, about 1.03% higher. The stock has experienced a current drawdown of -0.39% and exhibits annualized volatility of 41%.

- Nearest support level: ₹1721.93
- Nearest resistance level: ₹1743.77
- Daily trend shows consolidation with price below short-term moving averages.
- Weekly and monthly Supertrends remain bullish.
- Watch for a sustained move above ₹1743.77 or a break below ₹1721.93 for potential trend confirmation.

- Inside Bar
- Evening Star
- Doji
- Harami
- Bullish Engulfing Reversal
- Outside Bar
- Shooting Star

### News Context

Poly Medicure Limited held its 31st Annual General Meeting (AGM) on September 5, 2026, conducted via video conferencing. During the AGM, the company's audited standalone and consolidated financial statements for the fiscal year ending March 31, 2026, were adopted. Shareholders approved the declaration of a dividend on equity shares and the re-appointment of directors Rishi Baid and Devendra Raj Mehta. Additionally, the re-appointment of cost auditor M/s. Jai Prakash & Company was confirmed. The company noted that the statutory and secretarial audit reports for the period contained no qualifications. The voting results from the AGM were submitted to the exchange on September 7, 2026. In other news, Poly Medicure Limited's officials were scheduled to meet with Sumitomo Mitsui DS Asset Management on September 8, 2026, for a one-on-one discussion. This meeting was subject to change and was not expected to involve the disclosure of unpublished price-sensitive information.

- Poly Medicure Limited held its 31st AGM on September 5, 2026, adopting financial statements for the year ended March 31, 2026, and approving director re-appointments and a dividend.
- The company submitted the scrutinizer's report and voting results of the AGM to the exchange on September 7, 2026.
- An investor meeting with Sumitomo Mitsui DS Asset Management was scheduled for September 8, 2026, with no unpublished price-sensitive information to be shared.

- Poly Medicure Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 05, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Poly Medicure Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 05, 2026 |SUBJECT: Shareholders meeting
- Poly Medicure Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- POLYMED: Intimation On Rescheduling Of Investor/Analyst Meet |SUBJECT: General Updates
- Intimation for the schedule of Investors/Analyst Call/ Meet. |SUBJECT: General Updates

### What Changed

As of September 18, 2026, Poly Medicure (POLYMED) on the NSE is trading at ₹1726.0. This represents a slight increase from its previous price of ₹1712.7. The available evidence does not indicate any new filings or news developments for the company. The company's continuing context remains its profile as Poly Medicure listed on the NSE.

- On September 18, 2026, Poly Medicure's stock price was ₹1726.0.
- The stock price on September 18, 2026, was higher than the previous price of ₹1712.7.
- No new filings or news were reported for Poly Medicure as of September 18, 2026.
- Poly Medicure continues to be listed on the NSE.

### Official Filings

Poly Medicure Limited held its 31st Annual General Meeting (AGM) on September 5, 2026, where shareholders approved the audited financial statements for the fiscal year ending March 31, 2026. The meeting also saw the declaration of a final dividend of ₹3.50 per equity share, representing 70% of the share's face value of ₹5. Shareholder approval was granted for the re-appointment of directors Rishi Baid and Devendra Raj Mehta, along with the re-appointment of M/s. Jai Prakash & Company as the cost auditor for the fiscal year ending March 31, 2027. The company also confirmed that the statutory and secretarial audit reports for the fiscal year 2025-26 were unqualified. In the lead-up to the AGM, the company had communicated with shareholders regarding the meeting arrangements and dividend payment procedures, emphasizing the need to update PAN, KYC, nomination, and bank details for electronic dividend disbursement. Separately, Poly Medicure Limited has been actively engaging in investor relations, with scheduled one-on-one meetings with various asset management firms, including Sumitomo Mitsui DS Asset Management, Waswas Global, Bandhan AMC, Sparx Capital, Wasatch Global, and Bajaj Alternative Investment Ltd., between August 17 and September 8, 2026. The company has stated that no unpublished price-sensitive information will be shared during these interactions.

- The 31st Annual General Meeting was held on September 5, 2026.
- A final dividend of ₹3.50 per equity share was declared for FY 2025-26.
- The record date for the dividend payment was August 29, 2026.
- Re-appointments of directors Rishi Baid and Devendra Raj Mehta were approved.
- The company conducted multiple investor and analyst meetings between August 17 and September 8, 2026.

- Poly Medicure Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 05, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Poly Medicure Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 05, 2026 |SUBJECT: Shareholders meeting
- Poly Medicure Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- POLYMED: Intimation On Rescheduling Of Investor/Analyst Meet |SUBJECT: General Updates
- Intimation for the schedule of Investors/Analyst Call/ Meet. |SUBJECT: General Updates
- Poly Medicure Limited has informed the Exchange about the schedule of Investors/Analysts Call/Meet |SUBJECT: General Updates
- Poly Medicure Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Poly Medicure Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- Poly Medicure Limited has informed the Exchange about Shareholders meeting |SUBJECT: Shareholders meeting
- Poly Medicure Limited has informed the Exchange that Record date for the purpose of Dividend is 29-Aug-2026. |SUBJECT: Record Date

### Fundamentals

Poly Medicure's recent operating performance shows a mixed trend across its reported quarters. Revenue from operations saw an increase from ₹493.66 crore in Q3 FY2025-26 to ₹534.51 crore in Q4 FY2025-26, before slightly declining to ₹525.38 crore in Q1 FY2026-27. Profit Before Tax followed a similar pattern, rising from ₹95.93 crore in Q3 FY2025-26 to ₹83.51 crore in Q4 FY2025-26, and then increasing to ₹115.75 crore in Q1 FY2026-27. The net profit, or Profit Loss For Period, mirrored this, moving from ₹70.81 crore in Q3 FY2025-26 to ₹65.04 crore in Q4 FY2025-26, and then to ₹85.27 crore in Q1 FY2026-27. The company's finance costs remained relatively stable, ranging from ₹5.96 crore to ₹6.50 crore over the same periods. The difference between Profit Before Exceptional Items And Tax and Profit Before Tax was notable in Q3 FY2025-26 (₹102.73 crore vs ₹95.93 crore), suggesting potential exceptional items impacting that quarter's pre-tax profit, though this difference was not present in Q4 FY2025-26 or Q1 FY2026-27. Investors may want to monitor revenue growth consistency and the factors influencing profitability margins.

- Revenue from operations was ₹493.66 crore in Q3 FY2025-26, ₹534.51 crore in Q4 FY2025-26, and ₹525.38 crore in Q1 FY2026-27.
- Profit Loss For Period was ₹70.81 crore in Q3 FY2025-26, ₹65.04 crore in Q4 FY2025-26, and ₹85.27 crore in Q1 FY2026-27.
- Profit Before Tax was ₹95.93 crore in Q3 FY2025-26, ₹83.51 crore in Q4 FY2025-26, and ₹115.75 crore in Q1 FY2026-27.
- Finance Costs were ₹5.96 crore in Q3 FY2025-26, ₹6.41 crore in Q4 FY2025-26, and ₹6.50 crore in Q1 FY2026-27.

### Bull Case

Poly Medicure's technical indicators suggest a constructive setup across multiple timeframes as of September 18, 2026. The weekly trend shows a bullish Super Trend signal at ₹1351.41, with a positive EMA 20 slope of 45.02 and a rising ADX of 30.64, indicating strengthening upward momentum. Daily indicators also point to bullish conditions, with the Super Trend at ₹1680.77 and a positive SMA 50 slope of 5.82. While the daily EMA 20 slope is currently negative at -8.07, the overall trend across weekly and daily charts suggests potential for upward movement, supported by a positive ADX of 13.99 on the daily chart.

- Weekly Super Trend is bullish at ₹1351.41 with a positive EMA 20 slope of 45.02.
- Daily Super Trend is bullish at ₹1680.77.
- Daily SMA 50 shows a positive slope of 5.82.
- The stock is trading near its nearest support level of ₹1721.93 (as of 2026-09-18).

### Bear Case

Poly Medicure's technical indicators suggest potential headwinds. The daily trend shows the 20-day Exponential Moving Average (EMA) at ₹1729.47 with a negative slope of -8.07 over 5 periods, and the 20-day Simple Moving Average (SMA) at ₹1730.27 with a steeper negative slope of -12.9 over 5 periods. While the 50-day SMA shows a positive slope of 5.82, the overall daily trend indicators, including the Average Directional Index (ADX) at 13.99, point towards a lack of strong directional momentum. The company has experienced a maximum drawdown of -58% and a current drawdown of -39%, indicating significant past price depreciation. Furthermore, the 1-year return stands at -16%, and the year-to-date (YTD) return is -1%. The monthly trend shows the 20-day EMA at ₹1797.33 and the 20-day SMA at ₹1836.28, both higher than the current price, suggesting a potential resistance level. The nearest identified resistance level is ₹1743.77, approximately 1.03% above the current price of ₹1726.0.

- The daily trend shows a negative slope for the 20-day EMA (-8.07) and SMA (-12.9) over 5 periods as of 2026-09-18.
- The company has experienced a maximum drawdown of -58% and a current drawdown of -39%.
- The 1-year return is -16% and the year-to-date return is -1% as of 2026-09-18.
- The nearest resistance level is ₹1743.77, which is 1.03% above the current trading price of ₹1726.0.

### FAQs

**What recent corporate events has Poly Medicure Limited announced?**

Poly Medicure Limited held its 31st Annual General Meeting on September 5, 2026, where audited financial statements for the year ended March 31, 2026, were adopted, and a dividend was declared. The company also announced that officials would meet with Sumitomo Mitsui DS Asset Management on September 8, 2026. Previously, the company rescheduled an investor meeting with Waswas Global to August 27, 2026, and scheduled meetings with Bandhan AMC for August 27, 2026, and Sparx Capital for August 31, 2026. All meetings confirmed that no unpublished price-sensitive information would be shared.

**How has Poly Medicure Limited's stock performed over different periods?**

As of September 18, 2026, Poly Medicure Limited's stock has shown varied returns across different timeframes. It experienced a 10% return over the last 3 months and a 35% return over the last 6 months. However, over the last year, the stock has seen a return of -16%, and since the start of trading, it has a return of -36%.

**What are the key technical indicators for Poly Medicure Limited as of September 18, 2026?**

As of September 18, 2026, Poly Medicure Limited's daily trend indicators show a closing price of ₹1726.0, with the 50-day Simple Moving Average (SMA) at ₹1723.94 and the 20-day Exponential Moving Average (EMA) at ₹1729.47. The SuperTrend indicator is 'bullish' at ₹1680.77. On a weekly basis, the SuperTrend is also 'bullish' at ₹1351.41, with the 20-day EMA at ₹1654.94. The monthly trend also indicates a 'bullish' SuperTrend at ₹749.83.

**What are the nearest support and resistance levels for Poly Medicure Limited?**

As of September 18, 2026, the nearest identified support level for Poly Medicure Limited is ₹1721.93, which is approximately 0.24% below the current price. The nearest resistance level is ₹1743.77, which is approximately 1.03% above the current price.

- Poly Medicure Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 05, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Poly Medicure Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 05, 2026 |SUBJECT: Shareholders meeting
- Poly Medicure Limited has informed the Exchange about General Updates |SUBJECT: General Updates
- POLYMED: Intimation On Rescheduling Of Investor/Analyst Meet |SUBJECT: General Updates
- Intimation for the schedule of Investors/Analyst Call/ Meet. |SUBJECT: General Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Downtrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,721.93
- Risk regime: Higher Price Risk

### Support levels
- 1682.35
- 1427.4499999999998
- 1405.1

### Resistance levels
- 1749
- 1778.825
- 2084.65

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.78% |
| return_10 | -2.41% |
| return_1m | -3.29% |
| return_1y | -16.43% |
| return_20 | -2.46% |
| return_3m | +9.71% |
| return_5 | -1.24% |
| return_6m | +34.94% |
| return_since_start | -35.59% |
| return_ytd | -0.95% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -58.10% |
| annualized_volatility | +41.23% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Growth Outpaces Profitability as Financing and Tax Expenses Rise

Poly Medicure Limited reported ₹525.38 crore in revenue for the quarter ended 30 June 2026, marking a 30.3% increase from the same period last year. Despite the top-line expansion, net profit fell to ₹85.27 crore, down 8.4% from the previous year. While earnings recovered from the fourth quarter of the prior fiscal year, they did not match the levels recorded twelve months ago. The gap between revenue growth and profit contraction coincided with an increase in finance costs and higher tax payments.

## Top-Line Performance
Total revenue from operations reached ₹525.38 crore in the quarter ended 30 June 2026. This represents a 30.3% year-over-year increase compared to ₹403.21 crore in the corresponding quarter of the previous fiscal year. Revenue has expanded over the past four quarters, rising from ₹403.21 crore in Q1 FY2025-26 to ₹534.51 crore in Q4 FY2025-26. 

In the current quarter, revenue experienced a sequential decline of 1.71% from ₹534.51 crore in the immediately preceding quarter. The year-over-year figure confirms scale expansion over the trailing twelve months.

## Profitability and Earnings Per Share
Profit before tax stood at ₹115.75 crore for the quarter. This marks a 38.6% sequential improvement from ₹83.51 crore in Q4 FY2025-26. However, on a year-over-year basis, pre-tax profit declined by 4.83% from ₹121.62 crore in Q1 FY2025-26.

Net profit followed a similar pattern. Profit for the period increased 31.11% sequentially to ₹85.27 crore, yet remained 8.39% lower than the ₹93.08 crore reported in the same quarter last year. Basic earnings per share rose to ₹8.49, up 29.82% from the previous quarter, but stayed 7.62% below the ₹9.19 recorded twelve months prior. Diluted EPS moved from ₹6.53 to ₹8.48 sequentially, remaining below the prior year’s ₹9.17.

## Operating and Financial Expenses
The divergence between top-line growth and bottom-line contraction aligns with increases in financing and tax obligations. Finance costs rose to ₹6.50 crore in the current quarter, a 120.38% increase from ₹2.95 crore in the same quarter last year. Sequentially, finance costs were relatively stable, increasing 1.45% from ₹6.41 crore in the prior quarter.

Tax expense also saw a sequential increase, rising 58.72% to ₹32.03 crore from ₹20.18 crore in Q4 FY2025-26. On a year-over-year basis, tax expense grew by 7.26% compared to ₹29.86 crore in Q1 FY2025-26. The effective tax rate applied to pre-tax profit increased from approximately 24.6% last year to 27.7% in the current quarter, contributing to the compression in net profit despite the sequential rebound in pre-tax earnings.

## Comprehensive Income
Comprehensive income for the period was ₹85.23 crore. Unlike net profit, which grew sequentially, comprehensive income decreased by 5.23% from ₹89.94 crore in the previous quarter. This difference occurs because comprehensive income captures additional value movements beyond standard net profit. The sequential decline indicates that these other comprehensive income components reduced total earnings in the current quarter compared to the prior one.

## Key Takeaway
The quarter demonstrates revenue expansion over the past year, confirming continued sales growth. However, profitability contracted relative to the prior year, driven by higher finance costs and tax payments. While earnings recovered from the previous quarter's low point, they did not reach the levels recorded twelve months ago. The financial results highlight a period where top-line momentum outpaced bottom-line performance due to shifting expense and tax dynamics.

### Ratios

## Official filings

- 2026-09-18 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_18092026173534_Intimation_Investors_call_.pdf)
- 2026-09-07 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_07092026193747_Covering_Merge_Final_Report_Signed_.pdf)
- 2026-09-05 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_05092026173651_Outcome_Signed.pdf)
- 2026-09-02 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_02092026163054_Intimation_Investors_call_signed.pdf)
- 2026-08-25 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_25082026225444_Intimation_Investors_call_Re-schedule_Signed.pdf)
- 2026-08-22 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_22082026154410_Intimation_Investors_call_signed.pdf)
- 2026-08-17 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_17082026182220_Intimation_Investors_call_signed.pdf)
- 2026-08-15 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_15082026230514_Press_Release_for_Advertisment_Signed.pdf)
- 2026-08-14 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_14082026205013_Letter_to_shareholders_Signed.pdf)
- 2026-08-14 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_14082026203838_Annual_Report_signed.pdf)
- 2026-08-14 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_14082026205802__Covering_Signed.pdf)
- 2026-08-14 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_5391_WebXMLFile_20260814_184219819.xml)
- 2026-08-14 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_14082026210056__Covering_Signed.pdf)
- 2026-08-14 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_14082026215440_Transcript_Signed.pdf)
- 2026-08-10 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_10082026173428_Statement_of_Deviation_Reg_32_upload.pdf)
- 2026-08-10 — Credit Rating Update: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_10082026172557_Monitoring_Report_30_06_2026_upload.pdf)
- 2026-08-08 — Management Change: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_5391_WebXMLFile_20260808_163743503.xml)
- 2026-08-08 — Management Change: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_ROID_95605_KMP_Doc.zip)
- 2026-08-08 — Management Change: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_5391_WebXMLFile_20260808_163727254.xml)
- 2026-08-08 — Management Change: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_5391_WebXMLFile_20260808_130127023.xml)
- 2026-08-08 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_5391_WebXMLFile_20260808_130029392.xml)
- 2026-08-08 — Generic Announcement: Poly Medicure Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_5391_WebXMLFile_20260808_163854392.xml)
- 2026-08-07 — Generic Announcement: Poly Medicure Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, on August 7, 2026. The board also approved the grant of 1,476 stock options and the allotment of 1,975 equity shares under the Employee Stock Option Scheme 2020. M/s. Jai Prakash & Company was re-appointed as Cost Auditors for FY 2026-27. Mr. Ravi Prakash resigned as Deputy Company Secretary and Compliance Officer, effective August 10, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_07082026145559_OUTCOME.pdf)
- 2026-08-07 — Generic Announcement: Poly Medicure Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, on August 7, 2026. The board also approved the grant of 1,476 stock options and the allotment of 1,975 equity shares under the Employee Stock Option Scheme 2020. M/s. Jai Prakash & Company was re-appointed as Cost Auditors for FY 2026-27. Mr. Ravi Prakash resigned as Deputy Company Secretary and Compliance Officer, effective August 10, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_07082026151542_OUTCOME.pdf)
- 2026-08-07 — Generic Announcement: Poly Medicure Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, on August 7, 2026. The board also approved the grant of 1,476 stock options and the allotment of 1,975 equity shares under the Employee Stock Option Scheme 2020. M/s. Jai Prakash & Company was re-appointed as Cost Auditors for FY 2026-27. Mr. Ravi Prakash resigned as Deputy Company Secretary and Compliance Officer, effective August 10, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/POLYMED_07082026151412_OUTCOME.pdf)

## News and market events

- 2026-09-06 — Economic Times: **Ahead of Market: 10 things that will decide stock market action on Monday** — Indian benchmark indices ended slightly higher on Friday, with the Sensex rising 363 points and Nifty closing below 23,898. Investors monitored global market cues, US economic data, and inflation reports, while stock-specific action drove intraday activity across major sectors in a sideways-moving market environment. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/ahead-of-market-10-things-that-will-decide-stock-market-action-on-monday/articleshow/133834844.cms)
- 2026-09-02 — News18: **Market Crash Today: 10 Stocks Defy Selloff, Rally Up To 8% on September 2** — IFCI is among the biggest gainers, surging 8.02% to Rs 94.26, followed by The New India Assurance Company, up 5.67% at Rs 196.3, and Poly Medicure, which gains 5.48% to Rs 1,852.6. — [Source](https://www.news18.com/business/markets/market-crash-today-10-stocks-defy-selloff-rally-up-to-8-on-september-2-ws-l-10305500.html)
- 2026-08-10 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty rises above 24,600 again; Poly Medicure up over 7%** — Sensex Today | Stock Market LIVE Updates: We are at the halfway mark of the first day of trade, and the markets are trading in a volatile space, as the Nifty index remains cautious. The index is looking to hold onto the 24,500 mark. The Nifty Bank is also under pressure, down 100 points. SBI, Adani Ports and HDFC Life are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-banks-midcaps-bajaj-fin-pfc-kaynes-ola-bharat-forge-share-price-liveblog-19965161.htm)
- 2026-08-07 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Sensex falls over 450 points; Nifty slips below 24,600** — Sensex Today | Stock Market Live Updates: We are halfway through the day's trade and the market is moving on a cautious note, but now has extended the cuts, while holding key levels, as the Nifty remains above 24,600 as it looks to move ahead. The Nifty Bank is down close to 300 points, falling below the 57,900 mark. Tech Mahindra, TCS and HCLTech are the top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-cas-tata-hero-pgel-lic-sci-sbi-ncc-premier-crompton-midcaps-share-price-liveblog-19963799.htm)
- 2026-08-07 — CNBC-TV18: **Q1 Results LIVE Updates: Hindalco reports earnings; SBI tops profit, NII estimates** — Q1 Results LIVE Updates: Three Nifty 50 companies, SBI, Hindalco and Titan, as well as Kaynes Tech, BEML, Aarti Pharmalabs, Azad Engineering, Godrej Consumer, JK Tyre, Jubilant Pharmova, Maharashtra Seamless, Lemon Tree Hotels, Oil India, PFC, ABB India, Poly Medicure, Ramco Cements, Prism Johnson, Raymond, Raymond Realty, Ratnamani Metals & Tubes, among other companies are reporting their earnings today. Earnings reactions come from LIC, Hero MotoCorp, PG Electroplast, Britannia, Sonata Software and other companies. Watch this space for all the LIVE result updates for Q1. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-sbi-hindalco-titan-lic-pg-electroplast-hero-britannia-pfc-abb-beml-kaynes-fortis-azad-engg-share-price-liveblog-19963817.htm)

## Business profile

**Strategic vision:** Manufactures and distributes medical devices and consumables globally.

### Business segments
- **Medical Devices and Consumables:** Manufactures and distributes a diverse range of medical devices and consumables across various medical specialties. Products include anesthesia disposables, infusion sets, catheters, and diagnostics disposables.

### Competitive strengths
- First Indian medical devices company to establish manufacturing operations outside India.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/polymed
Markdown representation: https://faxioms.com/stocks/polymed?render=md